Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)
Personalised or precision therapy for ovarian cancer is becoming more common, with some genetic mutations being responsive to new treatments such as PARP inhibitors.
There is pressure to make these new drugs available to a larger group of patients. Unfortunately the cost means that a “try it and see” approach is not feasible. This prospective review of 473 non-selected ovarian cancer patients looks at their genetic status seeking to determine the real incidence of these mutations.
Of these women, who presented consecutively at one centre of excellence with ovarian cancer, 26.4% were suitable for precision drug treatment. Most (20% of the total) were BRCA1/2 positive; the remainder usually non-epithelial subtype ovarian cancers had other susceptible ovarian cancer predisposition genetic mutations. The commonest mutation; P53 which is seen in up to 90% of all ovarian cancer was excluded from the study as no precision therapy is currently available for this group.
No comments:
Post a Comment